Aileron Therapeutics Inc . has turned to insiders for $30 million in Series E financing and secured full rights to a cancer drug designed to take the brakes off the tumor-suppressor gene p53. Cancers develop as the tumor-suppressing p53 gene becomes inactivated through mutation or through proteins that suppress its activity. Aileron has discovered a drug that may reactivate p53 when it’s being held down by MDM2 and MDMX proteins.
Help employers find you! Check out all the jobs and post your resume.
